EpimAb Biotherapeutics rakes in $120m Series C
EpimAb Biotherapeutics, a clinical stage biotech company, has secured $120 million in Series C financing.
EpimAb Biotherapeutics, a clinical stage biotech company, has secured $120 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination